RE: Reply to Rio-Vilariño and colleagues' article and misconception about YAP1 Ser 397 phosphorylation function
- PMID: 38773253
- PMCID: PMC11183050
- DOI: 10.1038/s41416-024-02720-9
RE: Reply to Rio-Vilariño and colleagues' article and misconception about YAP1 Ser 397 phosphorylation function
Conflict of interest statement
The author declares no competing interests.
Comment on
-
Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells.Br J Cancer. 2024 May;130(8):1402-1413. doi: 10.1038/s41416-024-02649-z. Epub 2024 Mar 11. Br J Cancer. 2024. PMID: 38467828 Free PMC article.
References
-
- Rio-Vilariño A, Cenigaonandia-Campillo A, García-Bautista A, Mateos-Gómez P, Schlaepfer MI, Del Puerto-Nevado L, et al. Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells. Br J Cancer. 2024;130:1402–13. doi: 10.1038/s41416-024-02649-z. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources